Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025
bit.ly/3QYtOx5
@AACR
Senti Biosciences
481 posts
Senti Biosciences
@SentiBio
Outsmarting complex diseases with more intelligent medicines
- Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 bit.ly/3QYtOx5 $SNTI #CellTherapy #CARNK @AACR #AACR25
- We’ve entered into a business combination agreement with Dynamics Special Purpose Corp. (Nasdaq: DYNS) to create a public company focused on Gene Circuit-engineered cell and gene therapies. Learn more here: bit.ly/3qamSPl
- Today we announced FDA clearance of our IND application for SENTI-202, a potential first-in-class, logic-gated treatment for acute myeloid leukemia. Learn more: bit.ly/3v4IMJY $SNTI #AML #CARNK
- Check out @timlu's article with @GENbio about programming "living medicines" for cell and gene therapies. genengnews.com/insights/gene-… #genecircuits #genetherapy #celltherapy #syntheticbiology
- #News: Excited to share we completed our business combination with DYNS and debut as a public company as $SNTI on @Nasdaq today! Plan to advance lead #oncology programs toward IND filings in 2023. Learn more: bit.ly/3zpFUHV #syntheticbiology #genecircuits
- Interested in a career in synthetic biology? Save your spot to hear from @timlu on the career panel at the Mammalian Synthetic Biology Workshop & be sure to explore open opportunities at careers.sentibio.com. lnkd.in/gVhvPPy #syntheticbiology #biotech #genecircuits
- Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment on Wednesday, April 23rd at 4:00 PM ET bit.ly/42Oz4ty $SNTI #CellTherapy #CARNK #AML #AcuteMyeloidLeukemia
- Dr. Timothy Lu, CEO and Co-Founder of Senti Bio, conveys his confidence in Dr. Trager joining the Company’s SAB, as Dr. Trager brings over 25 years of experience in research & product development which will help keep $SNTI technology moving forward. bit.ly/4cxUPBs
- We're grateful for the fantastic opportunity at #JPM20 to share our latest updates and all the exciting things we have in store this year. Follow us to stay connected. #genecircuits #syntheticbiology #lifesciences
- We're pleased to announce that our CEO and Co-Founder @TimLu will be presenting at the 40th Annual @JPMorgan Healthcare Conference on January 11th at 2PM EST. Learn more here: bit.ly/3t3BrHQ #JPM22
- #News: Excited to share we've secured $105 million in our Series B financing, led by @LeapsByBayer, to support development of next-gen cell & gene therapies with our #genecircuit technology platform. #syntheticbiology #biotech #celltherapy #genetherapy lnkd.in/g6hRe3T
- Today, we announced positive initial clinical data from the Phase 1 trial of SENTI-202, a potential first-in-class, off-the-shelf #CARNK #celltherapy for R/R hematologic malignancies, including #AML. Learn more on our webcast on Dec. 3 at 7:30am ET: bit.ly/4eUaKtb $SNTI
- In collaboration with Celest, patient dosing commenced in the clinical trial of SN301A in #HCC. Celest is evaluating the safety and preliminary anti-tumor activity of SN301A, utilizing our #CARNK investigational #celltherapy SENTI-301A #GeneCircuit $SNTI: bit.ly/49EBE7j
